These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25453270)

  • 1. Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models.
    Hittinger M; Juntke J; Kletting S; Schneider-Daum N; de Souza Carvalho C; Lehr CM
    Adv Drug Deliv Rev; 2015 May; 85():44-56. PubMed ID: 25453270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Year in Review IV: Interstitial lung disease, cystic fibrosis, pulmonary infections, and mycobacterial disease.
    Tino G
    Proc Am Thorac Soc; 2006 Nov; 3(8):650-3. PubMed ID: 17065369
    [No Abstract]   [Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic treatment of CF lung disease: from bench to bedside.
    Bals R; Hubert D; Tümmler B
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S146-51. PubMed ID: 21658633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies.
    d'Angelo I; Conte C; La Rotonda MI; Miro A; Quaglia F; Ungaro F
    Adv Drug Deliv Rev; 2014 Aug; 75():92-111. PubMed ID: 24842473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled antimicrobial therapy - barriers to effective treatment.
    Weers J
    Adv Drug Deliv Rev; 2015 May; 85():24-43. PubMed ID: 25193067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhalation Delivery of Host Defense Peptides (HDP) using Nano- Formulation Strategies: A Pragmatic Approach for Therapy of Pulmonary Ailments.
    Adlakha S; Sharma A; Vaghasiya K; Ray E; Verma RK
    Curr Protein Pept Sci; 2020; 21(4):369-378. PubMed ID: 31889487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled antimicrobial therapy: from cystic fibrosis to the flu.
    O'Riordan TG
    Respir Care; 2000 Jul; 45(7):836-45. PubMed ID: 10926381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
    Westerman EM; Heijerman HG; Frijlink HW
    Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A liposome model to treat pseudomonas in lungs of cystic fibrosis and immune compromised patients.
    Yatvin MB
    Cell Mol Biol Lett; 2002; 7(2):304. PubMed ID: 12097974
    [No Abstract]   [Full Text] [Related]  

  • 11. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.
    Lim YH; Tiemann KM; Hunstad DA; Elsabahy M; Wooley KL
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Nov; 8(6):842-871. PubMed ID: 27016134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus.
    De Groote MA; Johnson L; Podell B; Brooks E; Basaraba R; Gonzalez-Juarrero M
    J Antimicrob Chemother; 2014 Apr; 69(4):1057-64. PubMed ID: 24222613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of azithromycin in patients with cystic fibrosis.
    Yousef AA; Jaffe A
    Paediatr Respir Rev; 2010 Jun; 11(2):108-14. PubMed ID: 20416547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic therapy for pulmonary exacerbations in adults with cystic fibrosis.
    Elpern EH; Patel G; Balk RA
    Medsurg Nurs; 2007 Oct; 16(5):293-8; quiz 299. PubMed ID: 18072667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection.
    McCaughey G; Gilpin D; Elborn J; Tunney MM
    Expert Rev Respir Med; 2013 Aug; 7(4):385-96. PubMed ID: 23964628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it.
    Duff AJ; Latchford GJ
    J Cyst Fibros; 2010 Dec; 9(6):455-6. PubMed ID: 20840889
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro bacterial isolate susceptibility to empirically selected antimicrobials in 111 dogs with bacterial pneumonia.
    Proulx A; Hume DZ; Drobatz KJ; Reineke EL
    J Vet Emerg Crit Care (San Antonio); 2014; 24(2):194-200. PubMed ID: 24382329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
    Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
    J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Infections with atypical mycobacteria in children].
    Heier I; Knudsen PK; Wathne KO
    Tidsskr Nor Laegeforen; 2003 Mar; 123(6):800-2. PubMed ID: 12693120
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibiotic use in cystic fibrosis.
    Eisenberg JD
    Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.